St. Michael’s Hospital’s Upstream Lab uncovers new evidence which could shape decisions on Paxlovid use for COVID-19

Studies suggest Paxlovid may not prevent severe COVID-19 outcomes in vaccinated individuals but could reduce recovery time and viral load.

If It's COVID, Paxlovid? Studies Suggest a Rethink These Days

The American College of Physicians updated outpatient COVID-19 treatment guidelines, outlining best practices for medication use in confirmed cases.

ACP updates outpatient COVID-19 treatment guidance

Japan approved the preventive use of the oral COVID-19 antiviral Xocova, marking the first authorization of its kind globally.

Japan approves preventive use of oral COVID drug Xocova in world first

Antiviral drug "Paquirovid(R) Pack 600/300" received approval for additional indication for children aged 6 years and older and weighing 20 kg or more - New treatment option for patients infected with COVID-19 -

Shionogi announced approval in Japan of Xocova (ensitrelvir fumaric acid) for post-exposure prophylaxis of COVID-19 based on positive phase 3 trial results demonstrating prevention of infection.

Shionogi Announces Approval in Japan of a Supplemental Indication for Xocova® (Ensitrelvir Fumaric Acid) for the Post-Exposure Prophylaxis of COVID-19.

antiviral news

Press Releases in the global landscape